CSBR NASDAQ
Credit Risk of going bust: lower than 73% of companies Debt: 14.0% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.01 (down 99.7%), Champions Oncology, Inc. would be worth roughly what it owes.
Total debt $11.0M against a stock market value of $67.6M.
Distance to default 8.19 (Merton model): prices to 2026-10-26, balance sheet 2026-07-31, debt counted $869K (short-term plus half of long-term), stock volatility 52.8%; Altman Z'' -7.91. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Hackensack, NJ 07601
US
Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle. Additionally, Champions Oncology offers Lumin Bioinformatics, a comprehensive software platform and data tool filled with insights from research services and clinical studies, accessible through annual subscriptions. The company distributes its offerings through various channels, including online platforms, word-of-mouth referrals, and a dedicated sales team, reaching both patients and healthcare professionals. Established in 1985, Champions Oncology, Inc. is based in Hackensack, New Jersey, and was formerly known as Champions Biotechnology, Inc. until its name change in April 2011.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| ACKERMAN JOEL | M-Exempt | 69,794 | $1.60 | 2026-10-15 |
| ACKERMAN JOEL | M-Exempt | 69,794 | $1.60 | 2026-10-15 |
| Breitfeld Philip P. | A-Award | 13,790 | $6.80 | 2025-11-05 |
| SIDRANSKY DAVID | A-Award | 21,216 | $6.80 | 2025-11-05 |
| Mendelson Daniel New | A-Award | 13,790 | $6.80 | 2025-11-05 |